Pfizer gets mixed results on psoriasis study; Sample6 raises $11M; Alkermes preps for PhIII launch;

@FierceBiotech: Popular from FierceCRO - Analyst: Bet on another boom for big CROs. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: 10 top drugs in biopharma's late-stage pipeline. Special report | Follow @JohnCFierce

@DamianFierce: Time to find out whether device firms are allowed at the biotech IPO party: LDR prices a $75M debut. News | Follow @DamianFierce

@EmilyMFierce: Altered antimicrobials could combat drug-resistant bacteria. ICYMI from FierceBiotech Research | Follow @EmilyMFierce

> Pfizer ($PFE) today revealed that its late-stage showdown comparing tofacitinib with Enbrel for psoriasis hit the non-inferior endpoint at the high dose but failed at the low dose. Release

> Canaan Partners has led an $11 million round for Sample6, a Boston based biotech focused on food safety. Release

> Alkermes ($ALKS) reports that it's ready to push into Phase III early next year with ALKS-5461, a new treatment for major depression. Release

Medical Device News

@FierceMedDev: ICYMI: Med tech's hottest takeover targets for the rest of 2013. Special report | Follow @FierceMedDev

> Boston Scientific touts positive data for PAD catheter. More

> Medtronic jumps into hemodialysis business through India partnership. Story

> Medtronic wins FDA panel support to expand pacemaker and defibrillator use. Item

Pharma News

@FiercePharma: Tops this AM on our website: Novartis eyes sell-offs, with decision on individual units expected soon. More | Follow @FiercePharma

@EricPFierce: Ranbaxy shopping for FDA approved plant. Article | Get all FiercePharmaManufacturing headlines via email | Follow @EricPFierce

@CarlyHFierce: GSK has always said it would be difficult to copy its respiratory drug Advair--and Teva agrees. Article | Follow @CarlyHFierce

> Former Lilly scientists indicted for passing R&D secrets to Chinese drugmaker. More

> Drugmakers want to block Maine from cheaper Canadian drugs. News

> Who'd like Tom Hanks to be their diabetes role model? Story

Drug Delivery News

@MichaelGFierce: Stem cell 'drug factories' target, treat inflammation. More | Follow @MichaelGFierce

> U.S.-based scientists win Nobel Prize for cell transport exploration. Item

> Study: Disc-shaped nanoparticles best at crossing cell membranes. More

> Cook touts positive data for Zilver paclitaxel-eluting stent after April recall. Story

> Alnylam posts positive PhI for RNAi cholesterol drug. Report

Diagnostics News

@MarkHFierce: Sign up for your free, weekly dose of FierceDiagnostics. Sign up here | Follow @MarkHFierce

> Roche looks to the future with two new molecular Dx systems. Article

> Exact Sciences denies talks underway to invest in Israeli cancer Dx startup. Story

> Boreal Genomics pulls in $18M Series C for genomic research and Dx test expansion. Report

> Renishaw Diagnostics seals deal with tech transfer group to develop infectious disease tests. More

And Finally… A new Rand study concludes that the ability to deliver high-quality care is a major factor in determining job satisfaction for a physician. A major source of dissatisfaction: Electronic medical records. Release

Suggested Articles

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.

Two long noncoding RNAs called TROLL-2 and TROLL-3 influence protein signaling to drive the progression of breast cancer, a new study revealed.